Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Is it possible to achieve TFR with low-dose TKI therapy?

Giuseppe Saglio • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia Asciminib Imatinib

Giuseppe Saglio, MD, University of Turin, Turin, Italy, discusses the possibility of achieving treatment-free remission (TFR) with low-dose tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML). According to Prof. Saglio, whilst the recommended dose of imatinib should not be reduced, it may be possible to give a lower dose of second or third-generation TKIs. Alternatively, combining two TKIs in a lower dose could help maintain treatment efficacy while decreasing the toxicity of single TKIs. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Giuseppe Saglio

2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
Giuseppe Saglio • 25 Oct 2022
3:20
The current standard of care in CML and insights into the use of first- and second-generation TKIs
Giuseppe Saglio • 25 Oct 2022
2:11
Addressing the issue of resistance to TKIs in CML
Giuseppe Saglio • 28 Oct 2022
3:35
TKI-related toxicities in CML & the importance of long-term monitoring
Giuseppe Saglio • 28 Sep 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals